Explore
Use this educational Retatrutide units calculator and dose escalation chart to better understand how dose, concentration, mL, syringe units, and vial size may work together. Retatrutide is not FDA-approved at this time. Florida Surgery and Weight Loss Center currently helps eligible patients access medical weight loss options such as tirzepatide and semaglutide when clinically appropriate.
This page includes a Retatrutide dose-to-units calculator, educational dose escalation chart, units conversion chart, and safety information for patients researching newer weight loss medications.
Because Retatrutide is still investigational, this page should be used for education only. Patients interested in medical weight loss should speak with a licensed provider about currently available options, including tirzepatide and semaglutide when clinically appropriate.
Florida Surgery and Weight Loss Center
Enter your values and press calculate.
🟢 Retatrutide is an investigational weight loss medication and is not FDA-approved at this time.
🟢 Retatrutide is being studied as a triple agonist that targets GLP-1, GIP, and glucagon pathways.
🟢 This calculator helps estimate mL, units, doses per vial, and weeks of medication based on concentration and dose.
🟢 Patients should not use research-grade or black-market Retatrutide products.
🟢 Florida Surgery and Weight Loss Center can help eligible patients explore medical weight loss options such as tirzepatide and semaglutide when clinically appropriate.
The chart below is an educational example based on commonly discussed Retatrutide dose levels in research settings. It is not a prescription, recommendation, or treatment plan.
| Stage | Example Dose | Purpose | Important Note |
|---|---|---|---|
| Starting Phase | 1–2 mg weekly | Lower starting exposure | Educational example only |
| Early Escalation | 4 mg weekly | Research dose level | Not an approved dosing schedule |
| Mid Escalation | 6–9 mg weekly | Higher research dose range | Requires clinical supervision in trials |
| Higher Research Dose | 12 mg weekly | Studied in obesity trials | Not FDA-approved |
This chart is informational only. Retatrutide dosing should not be copied from online charts, social media, or research discussions.
These examples show how syringe units may change depending on the concentration. This is for math education only.
| Dose | 5 mg/mL | 10 mg/mL | 20 mg/mL | 30 mg/mL |
|---|---|---|---|---|
| 1 mg | 20 units | 10 units | 5 units | 3.3 units |
| 2 mg | 40 units | 20 units | 10 units | 6.7 units |
| 4 mg | 80 units | 40 units | 20 units | 13.3 units |
| 6 mg | 120 units | 60 units | 30 units | 20 units |
| 9 mg | 180 units | 90 units | 45 units | 30 units |
| 12 mg | 240 units | 120 units | 60 units | 40 units |
Formula: dose in mg ÷ concentration in mg/mL = mL. Then mL × 100 = U-100 syringe units.
Retatrutide is an investigational medication being studied for obesity and metabolic health. It is often described as a triple agonist because it targets GLP-1, GIP, and glucagon pathways.
According to Lilly, Retatrutide is not currently FDA-approved and is still being evaluated in clinical trials. You can read Lilly’s patient-facing overview here: What to Know About Retatrutide.
Florida Surgery and Weight Loss Center can assist eligible patients with medical weight loss programs, including tirzepatide and semaglutide options when clinically appropriate.
While Retatrutide remains investigational, eligible patients may be able to access medical weight loss options that are currently available through provider-supervised programs.
Use these tools to better understand medication units, BMI, body composition, and weight loss program options.
Patients interested in wellness-focused support can also explore peptide therapy, dosing education, and at-home peptide calculator tools through Florida Surgery and Weight Loss Center.
Florida Surgery and Weight Loss Center is expanding medical weight loss support across participating states. Our team can help eligible patients understand available treatment options, medication instructions, pharmacy labeling, dose calculations, and provider-supervised weight loss care. Availability depends on provider evaluation, state participation, pharmacy requirements, and clinical eligibility.
No. Retatrutide is not FDA-approved at this time. It remains an investigational medication being studied in clinical trials.
Retatrutide is not currently FDA-approved for routine prescription use. Florida Surgery and Weight Loss Center can help eligible patients explore currently available medical weight loss options such as tirzepatide and semaglutide when clinically appropriate.
This calculator estimates dose volume in mL, U-100 syringe units, total medication in the vial, estimated doses per vial, and estimated weeks based on one injection per week.
No. This page is educational only. It does not provide a prescription, treatment plan, or dosing recommendation.
Eligible patients may be able to access medical weight loss options such as tirzepatide or semaglutide after provider evaluation. Not all patients qualify, and prescriptions are not guaranteed.
Retatrutide is not FDA-approved, but our team can help eligible patients review medical weight loss options that may be available now, including tirzepatide and semaglutide when clinically appropriate.
Call (954) 551-3508 Book Online“`
Real people, REAL RESULTS! Check out a few of the many people that we have helped reach their ideal weight goals over the years.
